![]() ![]() Due to the obscure symptoms at early stages and the aggressive progression of the disease, only around 15-20% of PDAC patients have a chance to receive radical surgery at diagnosis and most of the patients are detected the disease with unresectable advanced tumors. ![]() Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the United States and the seventh leading cause of cancer deaths in China. Inactive carrier(IC) and resolved HBV infection showed no significant association with survival compared to non HBV infection.Ĭonclusion: This study indicated that CHB infection may serve as an independent factor which decrease synchronous or metachronous liver metastasis, and increase overall survival among advanced PDAC patients. ![]() For stage IV patients, CHB infection was inversely associated with overall survival compared to non HBV infection (HR 0.70, 95% CI 0.51-0.95). In a multivariable Cox model, CHB infection (HR=0.11, 95% CI 0.02-0.82) is considered as a protective factor of metachronous liver metastasis compared to Non HBV infection for stage III patients. Results: In multivariable Logistic regression model, chronic hepatitis B(CHB) infection was inversely associated with synchronous liver metastasis compared to non HBV infection (OR 0.41, 95% CI 0.19-0.85) for stage IV patients. The association between HBV status and advanced PDAC progression was then examined. In this study, we collected 1,526 advanced PDAC patients at three participating hospitals - Shanghai Cancer Center, Changhai Hospital and Ruijin Hospital from 2004 to 2013. ![]() Methods: A multicenter cohort study was conducted to explore whether liver metastasis and overall survival in locally advanced and metastatic PDAC could be affected by HBV infection. Therefore, we conducted this study to assess the effect of HBV infection on PDAC progression among a large cohort in China. Purpose: Whether the progression of advanced pancreatic ductal adenocarcinoma (PDAC) patients could be affected by HBV exposure remains to be determined. Received: MaAccepted: JPublished: NovemAbstract * These authors have contributed equally to this study He is also a frequent consultant to professional organizations, non-profit organizations and start-ups.Qiwen Chen 1,2,*, Zhouyu Ning 1,*, Lei Wang 3,*, Haifeng Ying 4,*, Shu Dong 1,*, Chenyue Zhang 1,*, Xiaoheng Shen 4, Yuanbiao Guo 4, Hao Chen 1, Xiaoyan Zhu 1, Yehua Shen 1, Weidong Shi 1, Yongqiang Hua 1, Kun Wang 1, Junhua Lin 1, Litao Xu 1, Lianyu Chen 1, Lanyun Feng 1, Xiumei Zhang 1, Jing Xie 1, Bo Sun 5, Yaqin Sun 6, Wenchao Gu 6, Mei Kang 2, Zheng Tang 2, Zhujun Chen 7, Zhen Chen 1, Luming Liu 1, Jinming Yu 2, Zhaoshen Li 3 and Zhiqiang Meng 1ġ Department of Integrative Oncology and Department of Oncology, Fudan University, Shanghai Cancer Center, Shanghai Medical College, Shanghai, ChinaĢ Institute of Clinical Epidemiology, Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai, Chinaģ Digestive Endoscopy Center, Department of Gastroenterology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, ChinaĤ Department of Integrative Medicine of Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Chinaĥ Department of Endoscopy and Department of Oncology, Fudan University, Shanghai Cancer Center, Shanghai Medical College, Shanghai, ChinaĦ Department of Radiology and Department of Oncology, Fudan University, Shanghai Cancer Center, Shanghai Medical College, Shanghai, Chinaħ Department of Clinical Laboratory and Department of Oncology, Fudan University, Shanghai Cancer Center, Shanghai Medical College, Shanghai, China Runhuan’s research has been recognized in the practitioners’ community through his applied technical contributions and presentations as invited speakers at industry conferences. He co-founded the Illinois Risk Lab, which facilitates research activities that integrate experiential learning for Illinois students and address industrial problems. He is an Associate Editor of North American Actuarial Journal, Methodology and Computing in Applied Probability, and Quantitative Finance and Economics. As an applied scientist, Runhuan strongly believes that most interesting research problems are discovered in response to the changing needs of the industry and the society. He has published extensively on top-tier actuarial and quantitative finance journals. He has a wide spectrum of research interests in mathematics and economics of risk and uncertainty in the financial world. Runhuan Feng, FSA, CERA, is a Professor, the Director of Actuarial Science, the State Farm Companies Foundation Scholar in Actuarial Science and a Helen Corley Petit Professorial Scholar at the University of Illinois. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |